Gut–Brain Axis and Diabetes

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Endocrinology and Metabolism Research".

Deadline for manuscript submissions: 31 May 2026 | Viewed by 2700

Special Issue Editor


E-Mail Website
Guest Editor
Department of Physiology, Anatomy and Neuroscience, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary
Interests: enteric nervous system; gastroenterology; diabetes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bidirectional communication along the gut–brain axis is fundamental in health and diseases. This close and sensitive relationship between the gastrointestinal system and brain is greatly affected in diabetes. Gastrointestinal symptoms or neuronal-damage-affected central and peripheral nervous systems are common in diabetic patients. Diabetic microbial dysbiosis, chronic low-grade inflammation, and immune responses have critical roles in modulating the gut–brain axis. Gut-derived bacterial metabolites trigger the neuro-inflammatory processes in the enteric nervous system and modulate the brain functions. Gut hormones secreted by enteroendocrine cells are also able to activate the enteric, spinal, or vagal nerve endings, creating critical links among them.

The aim of this Special Issue is to highlight the effects of diabetes on critical elements of the gut–brain axis influencing both gastrointestinal and brain functions. This Special Issue is open for original research articles as well as review articles.

Dr. Nikolett Bódi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • gut–brain axis
  • enteric nervous system
  • central nervous system
  • microbiota
  • enteroendocrine cells
  • inflammation
  • immune responses

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1767 KB  
Article
Assessing Plasma C-Peptide Levels and Their Relationship with Health-Related Quality of Life in Patients with Prediabetes and Type 1 and Type 2 Diabetes
by Sajid Iqbal, Silvia Reverté-Villarroya, Nayab Batool Rizvi, Hira Butt and Josep Lluís Clúa-Espuny
Biomedicines 2025, 13(10), 2423; https://doi.org/10.3390/biomedicines13102423 - 3 Oct 2025
Viewed by 2123
Abstract
Background/Objectives: Understanding the relationship between plasma connecting peptide (C-peptide) levels and health-related quality of life (HRQoL) can inform diabetes management strategies. This study aimed to assess plasma C-peptide levels, HRQoL, and their association in patients with prediabetes, type 1 diabetes (T1D), and type [...] Read more.
Background/Objectives: Understanding the relationship between plasma connecting peptide (C-peptide) levels and health-related quality of life (HRQoL) can inform diabetes management strategies. This study aimed to assess plasma C-peptide levels, HRQoL, and their association in patients with prediabetes, type 1 diabetes (T1D), and type 2 diabetes (T2D) attending outpatient departments (OPDs) in tertiary care hospitals. Methods: A cross-sectional survey was conducted between 1 January and 30 June 2023, using the EuroQoL Five Dimensions (EQ-5D-5L) instrument. Participants with prediabetes, T1D, or T2D were recruited from OPDs in diabetology, endocrinology, general practice, and family medicine at Sheikh Zayed Hospital (SZH) and Mayo Hospital (MH) in Pakistan. Plasma C-peptide levels were measured and HRQoL was assessed using EQ-5D-5L and the EQ Visual Analog Scale (VAS). Results: A total of 301 patients were included: 42 with prediabetes (14%), 70 with T1D (23.2%), and 189 with T2D (62.8%). The median C-peptide level was 0.46 nmol/L (IQR 0.13–0.85), the HRQoL score was 78.5% (IQR 63.2–100%), and the EQ VAS score was 85% (IQR 70–90%). C-peptide levels were significantly correlated with HRQoL scores (r = 0.14, p < 0.02) and differed across mobility, daily activity, pain/discomfort, and anxiety/depression domains (all p < 0.02). HRQoL scores significantly varied among the three groups (p < 0.0001), particularly in the aforementioned domains. Conclusions: C-peptide levels and HRQoL differ significantly across diabetes types, with lower C-peptide associated with reduced mobility, increased pain, and mental health issues. These findings underscore the importance of targeting C-peptide regulation to enhance HRQOL in diabetic populations. Full article
(This article belongs to the Special Issue Gut–Brain Axis and Diabetes)
Show Figures

Graphical abstract

Back to TopTop